KKR & Co: Q2 Earnings Insights

  KKR & Co (NYSE:KKR) reported its Q2 earnings results on Tuesday, August 2, 2022 at 06:50 AM. Here's what investors need to know about the announcement. Earnings KKR & Co reported in-line EPS of $0.95 versus an estimate of $0.95.

 

KKR & Co (NYSE:KKR) reported its Q2 earnings results on Tuesday, August 2, 2022 at 06:50 AM.

Here’s what investors need to know about the announcement.

Earnings

KKR & Co reported in-line EPS of $0.95 versus an estimate of $0.95.

Revenue was up $38.00 million from the same period last year.

Past Earnings Performance

Last quarter the company beat on EPS by $0.12 which was followed by a 5.64% increase in the share price the next day.

Here’s a look at KKR & Co’s past performance:

 

Quarter Q1 2022 Q4 2021 Q3 2021 Q2 2021
EPS Estimate 0.98 1.21 0.93 0.83
EPS Actual 1.10 1.59 1.05 1.05
Revenue Estimate 1.73B 1.88B 1.50B 1.35B
Revenue Actual 1.90B 2.22B 1.70B 1.74B

To track all earnings releases for KKR & Co visit their earnings calendar here.

This article was generated by Benzinga’s automated content engine and reviewed by an editor.

Total
0
Shares
Related Posts
Read More

Reported Late Wednesday, WuXi Biologics And GSK Enter Into License Agreement On Multiple Novel Bi- & Multi-specific T Cell Engagers; Wuxi Biologics Will Receive An Upfront Payment Of $40M And Tiered Royalties On Net Sales

WuXi Biologics will provide an exclusive license to GSK for one preclinical bi-specific T cell engaging (TCE) antibody and the option of three additional bi-/multi-specific TCE antibodies developed using WuXi

GSK